{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-028372","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2024-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.291064+00:00","generated_at":"2026-06-06T05:44:06.311024+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Autolus prices $350M ADS offering at $6.00 per ADS for obe-cel development","bullets":["Offering of 58,333,336 ADSs at $6.00/ADS for gross proceeds of $350 million.","Net proceeds to fund obe-cel clinical development, manufacturing, and commercial infrastructure.","Additionally expects $250 million from BioNTech under license/option agreement and private placement.","Offering expected to close February 12, 2024; Jefferies and Truist are joint bookrunners."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-028372","json":"https://secwatch.observer/filing/0001193125-24-028372.json","markdown":"https://secwatch.observer/filing/0001193125-24-028372.md","text":"https://secwatch.observer/filing/0001193125-24-028372.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000119312524028372/0001193125-24-028372-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000119312524028372/d745010d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T05:44:06.311024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7b2d3cf99a70fc42bb109d75e9d971544089d425","claim":"Autolus Therapeutics plc entered into Underwriting Agreement with Jefferies LLC and Truist Securities, Inc. as representatives of the several underwriters named therein valued at $350 million (effective 2024-02-08).","evidence_excerpt":"On February 8, 2024, Autolus Therapeutics plc (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Jefferies LLC and Truist Securities, Inc. as representatives of the several underwriters named therein (the “ Underwriters ”), in connection with the issuance and sale by the Company in an underwritten registered direct offering (the “ Offering ”) by the Company of 58,333,336 American Depositary Shares (“ ADSs ”) representing 58,333,336 ordinary shares of the Company at an offering price of $6.00 per ADS. Gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, are expected to be $350 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730463/000119312524028372/0001193125-24-028372-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Jefferies LLC and Truist Securities, Inc. as representatives of the several underwriters named therein"},{"label":"Value","value":"$350 million"},{"label":"Effective","value":"2024-02-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}